Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II clinical study of VE800 in combination with Opdivo (nivolumab) in advanced or metastatic cancers

Trial Profile

A phase I/II clinical study of VE800 in combination with Opdivo (nivolumab) in advanced or metastatic cancers

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 23 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; VE 800 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Sep 2019 According to a Vedanta Biosciences media release, the funding from recent series C-2 financing ($16.6 million) will support this trial.
    • 19 Nov 2018 New trial record
    • 06 Nov 2018 Acording to a Vedanta Biosciences media release, the company expects to initiate a clinical study of VE800 in mid-2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top